OR072 Viscous oral cromolyn for the treatment of eosinophilic esophagitis: a double-blind, placebo-controlled trial

Lieberman, Jay; Zhang, J.; Cavender, Cary P.

doi:10.1016/j.anai.2017.08.054

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fourteen studies reported change in absolute eosinophil counts before and after therapy or by percentage changes from baseline in eosinophil density. 23,24,[26][27][28][29][30]32,33,35,[37][38][39][40] One study used the EoE Histology Scoring System (EoE-HSS) to evaluate both severity and extent of 8 features (eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis). 38 Four studies specified that histologic outcomes required changes at multiple esophageal levels (eg, proximal and distal esophagus).…”

Section: Histology Outcome Definitionsmentioning

confidence: 99%

“…Eight studies reported histologic placebo remission rates of 0%. 20,21,23,24,28,33,39,40 When assessed as a continuous measure relative to the scale of the measurement tool, endoscopy scores before and after placebo administration changed between -0.6% to -16%. Larger variances were evident when assessing patient-reported placebo response ( Figure 2); patient-reported scores before and after placebo administration varied between -28.6% to þ36.6%.…”

Section: Histology Endoscopy and Patient-reported Placebo Ratesmentioning

confidence: 99%

See 1 more Smart Citation

Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review

Rhijn

Jairath

et al. 2018

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

Section: Histology Outcome Definitionsmentioning

confidence: 99%

Section: Histology Endoscopy and Patient-reported Placebo Ratesmentioning

confidence: 99%

Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review

Rhijn

Jairath

et al. 2018

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

Medical treatment of eosinophilic esophagitis

Franciosi

Gordon

Sinopoulou

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Eosinophilic esophagitis (EoE) is a chronic antigen‐mediated eosinophilic inflammatory disease isolated to the esophagus. As a clinicopathologic disorder, a diagnosis of EoE requires a constellation of clinical symptoms of esophageal dysfunction and histologic findings (at least 15 eosinophils/high‐powered microscope field (eos/hpf)). Current guidelines no longer require the failure of response to proton pump inhibitor medications to establish a diagnosis of EoE, but continue to suggest the exclusion of other etiologies of esophageal eosinophilia. The treatment goals for EoE are improvement in clinical symptoms, resolution of esophageal eosinophilia and other histologic abnormalities, endoscopic improvement, improved quality of life, improved esophageal function, minimized adverse effects of treatment, and prevention of disease progression and subsequent complications. Currently, there is no cure for EoE, making long‐term treatment necessary. Standard treatment modalities include dietary modifications, esophageal dilation, and pharmacologic therapy. Effective pharmacologic therapies include corticosteroids, rapidly emerging biological therapies, and proton pump inhibitor medications. Objectives To evaluate the efficacy and safety of medical interventions for people with eosinophilic esophagitis. Search methods We searched CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, and WHO ICTRP to 3 March 2023. Selection criteria Randomized controlled trials (RCTs) comparing any medical intervention or food elimination diet for the treatment of eosinophilic esophagitis, either alone or in combination, to any other intervention (including placebo). Data collection and analysis Pairs of review authors independently selected studies and conducted data extraction and risk of bias assessment. We expressed outcomes as a risk ratio (RR) and as the mean or standardized mean difference (MD/SMD) with 95% confidence interval (CI). We assessed the certainty of the evidence using GRADE. Our primary outcomes were: clinical, histological, and endoscopic improvement, and withdrawals due to adverse events. Secondary outcomes were: serious and total adverse events, and quality of life. Main results We included 41 RCTs with 3253 participants. Eleven studies included pediatric patients while the rest recruited both children and adults. Four studies were in patients with inactive disease while the rest were in patients with active disease. We identified 19 intervention comparisons. In this abstract we present the results of the primary outcomes for the two main comparisons: corticosteroids versus placebo and biologics versus placebo, based on the prespecified outcomes defined of the primary studies. Fourteen studies compared corticosteroids to placebo for induction of remission and the risk of bias for these...

show abstract

OR072 Viscous oral cromolyn for the treatment of eosinophilic esophagitis: a double-blind, placebo-controlled trial

Cited by 2 publications

References 0 publications

Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review

Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review

Medical treatment of eosinophilic esophagitis

Contact Info

Product

Resources

About